<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02741960</url>
  </required_header>
  <id_info>
    <org_study_id>SHDC12015902</org_study_id>
    <nct_id>NCT02741960</nct_id>
  </id_info>
  <brief_title>The Effect of Metformin on Reducing Lupus Flares</brief_title>
  <acronym>Met Lupus</acronym>
  <official_title>A Multicenter, Randomised, Double-blind Placebo Controlled Trial on the Efficacy and Safety of add-on Metformin to Conventional Immunosuppressants in Systemic Lupus Erythematosus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomised, double-blind placebo controlled trial on the efficacy and
      safety of add-on metformin to conventional immunosuppressants in systemic lupus erythematosus
      (SLE).

      The purpose of this study is to evaluate: 1) the effect of metformin on reducing disease
      flares; 2) the influence of metformin on corticosteroid sparing effect; 3) the influence of
      metformin on body mass index (BMI); 4) the safety of metformin.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 24, 2016</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>numbers of participants who remained at risk of flares at each visit</measure>
    <time_frame>one year</time_frame>
    <description>the effect of metformin on reducing disease flares</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>changes in prednisone dose from baseline at each visit</measure>
    <time_frame>one year</time_frame>
    <description>the influence of metformin on corticosteroid sparing effect</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>changes in BMI from baseline at each visit</measure>
    <time_frame>one year</time_frame>
    <description>the influence of metformin on BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of participants with treatment-related adverse events</measure>
    <time_frame>one year</time_frame>
    <description>the safety of metformin</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">180</enrollment>
  <condition>Systemic Lupus Erythematosus</condition>
  <arm_group>
    <arm_group_label>metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to metformin will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Eligible patients for clinical trial were randomized in a 1:1 ratio to metformin/placebo add-on. Subjects randomized to placebo will receive a target dose of 500 mg three times daily. Investigators were allowed to adjust the dose according to the patients' tolerance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>metformin</intervention_name>
    <description>500 mg metformin three times daily</description>
    <arm_group_label>metformin</arm_group_label>
    <other_name>Metformin Hydrochloride Tablets</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>500 mg placebo three times daily</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willingness of the subject to participate in the study, proven by signing the informed
             consent;

          -  Systemic lupus erythematosus (SLE), as defined by meeting at least 4 of 11
             classification criteria of American College of Rheumatology for the classification of
             systemic lupus erythematosus, either sequentially or coincidentally. The 4 criteria
             doesn't need to be present at the time of study enrollment;

          -  The course of SLE longer than1 year; and there is a clear record of disease flares in
             the past 1 year with prednisone more than 20mg/day;

          -  Patients with mild/moderate disease activity (score≤ 6 at screening on SLEDAI); no
             British Isles Lupus Assessment Group (BILAG) A or no more than one B;

          -  A stable treatment regimen with fixed doses of prednisone (≤ 20mg/day), antimalarial,
             or immunosuppressive drugs (azathioprine/ mycophenolate mofetil/ methotrexate/
             ciclosporin/ leflunomide/ thalidomide) for at least 30 days.

        Exclusion Criteria:

          -  Patients who are unwilling to sign the inform consent;

          -  Alanine aminotransferase (ALT)/ aspartate aminotransferase (AST) &gt; 2 times upper
             normal limits; creatinine clearance rate &lt; 60ml/min;

          -  Patients who used cyclophosphamide 6-months before screening; used biological agents
             12-months before screening;

          -  Previous exposure of metformin within 30 days before screening; or previous history of
             intolerant to metformin;

          -  Patients who diagnosed of diabetes mellitus;

          -  Pregnancy or lactation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuang Ye, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>RenJi Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ethics Committee of Renji Hospital, Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Wang H, Li T, Chen S, Gu Y, Ye S. Neutrophil Extracellular Trap Mitochondrial DNA and Its Autoantibody in Systemic Lupus Erythematosus and a Proof-of-Concept Trial of Metformin. Arthritis Rheumatol. 2015 Dec;67(12):3190-200. doi: 10.1002/art.39296.</citation>
    <PMID>26245802</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2016</study_first_submitted>
  <study_first_submitted_qc>April 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 18, 2016</study_first_posted>
  <last_update_submitted>December 18, 2017</last_update_submitted>
  <last_update_submitted_qc>December 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Shuang Ye</investigator_full_name>
    <investigator_title>Executive Director, Dept. Rheumatology, Renji Hospital South Campus</investigator_title>
  </responsible_party>
  <keyword>metformin</keyword>
  <keyword>systemic lupus erythematosus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lupus Erythematosus, Systemic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

